Penumbra (PEN) Free Cash Flow Growth (3y) (2017 - 2026)
Penumbra (PEN) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.30 Bn | 175.00 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 128.77 Bn | 125.89 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 67.85 Bn | 66.39 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 48.12 Bn | 44.45 Bn | 1.29 Bn | -27.72% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 77.20% |
| 7 | GE HealthCare Technologies | 27.98 Bn | 25.70 Bn | 1.98 Bn | -29.89% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.78 Bn | 20.65 Bn | 2.07 Bn | -0.27% |
| 10 | Penumbra | 12.57 Bn | 11.95 Bn | 253.41 Mn | 87.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.82% |
| Dec 31, 2025 | 77.56% |
| Sep 30, 2025 | 86.18% |
| Jun 30, 2025 | 33.90% |
| Mar 31, 2025 | 91.19% |
| Dec 31, 2024 | 55.85% |
| Sep 30, 2024 | 14.66% |
| Jun 30, 2024 | 138.84% |
| Mar 31, 2024 | 55.62% |
| Dec 31, 2023 | 173.35% |
| Sep 30, 2023 | 38.10% |
| Jun 30, 2023 | 37.73% |
| Mar 31, 2023 | 39.37% |
| Dec 31, 2022 | 45.59% |
| Sep 30, 2022 | -40.27% |
| Jun 30, 2022 | -133.76% |
| Mar 31, 2022 | -47.89% |
| Dec 31, 2021 | -73.84% |
| Sep 30, 2021 | 33.67% |
| Jun 30, 2021 | 10.35% |